Tags

Type your tag names separated by a space and hit enter

A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Nat Commun. 2021 02 03; 12(1):776.NC

Abstract

The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-2 vaccine a global health and economic priority. Taking advantage of versatility and rapid development, three SARS-CoV-2 mRNA vaccine candidates have entered clinical trials with a two-dose immunization regimen. However, the waning antibody response in convalescent patients after SARS-CoV-2 infection and the emergence of human re-infection have raised widespread concerns about a possible short duration of SARS-CoV-2 vaccine protection. Here, we developed a nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD, termed as mRNA-RBD. A single immunization of mRNA-RBD elicited both robust neutralizing antibody and cellular responses, and conferred a near-complete protection against wild SARS-CoV-2 infection in the lungs of hACE2 transgenic mice. Noticeably, the high levels of neutralizing antibodies in BALB/c mice induced by mRNA-RBD vaccination were maintained for at least 6.5 months and conferred a long-term notable protection for hACE2 transgenic mice against SARS-CoV-2 infection in a sera transfer study. These data demonstrated that a single dose of mRNA-RBD provided long-term protection against SARS-CoV-2 challenge.

Authors+Show Affiliations

CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. Shanxi Academy of Advanced Research and Innovation, Taiyuan, China.CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China. tanwj@ivdc.chinacdc.cn.University of Chinese Academy of Sciences, Beijing, China. gaof@im.ac.cn. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. gaof@im.ac.cn. Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. gaof@im.ac.cn.CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. yanjh@im.ac.cn. University of Chinese Academy of Sciences, Beijing, China. yanjh@im.ac.cn. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. yanjh@im.ac.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33536425

Citation

Huang, Qingrui, et al. "A Single-dose mRNA Vaccine Provides a Long-term Protection for hACE2 Transgenic Mice From SARS-CoV-2." Nature Communications, vol. 12, no. 1, 2021, p. 776.
Huang Q, Ji K, Tian S, et al. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun. 2021;12(1):776.
Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., Gao, G. F., & Yan, J. (2021). A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 12(1), 776. https://doi.org/10.1038/s41467-021-21037-2
Huang Q, et al. A Single-dose mRNA Vaccine Provides a Long-term Protection for hACE2 Transgenic Mice From SARS-CoV-2. Nat Commun. 2021 02 3;12(1):776. PubMed PMID: 33536425.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. AU - Huang,Qingrui, AU - Ji,Kai, AU - Tian,Siyu, AU - Wang,Fengze, AU - Huang,Baoying, AU - Tong,Zhou, AU - Tan,Shuguang, AU - Hao,Junfeng, AU - Wang,Qihui, AU - Tan,Wenjie, AU - Gao,George F, AU - Yan,Jinghua, Y1 - 2021/02/03/ PY - 2020/09/25/received PY - 2021/01/08/accepted PY - 2021/2/4/entrez PY - 2021/2/5/pubmed PY - 2021/2/13/medline SP - 776 EP - 776 JF - Nature communications JO - Nat Commun VL - 12 IS - 1 N2 - The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-2 vaccine a global health and economic priority. Taking advantage of versatility and rapid development, three SARS-CoV-2 mRNA vaccine candidates have entered clinical trials with a two-dose immunization regimen. However, the waning antibody response in convalescent patients after SARS-CoV-2 infection and the emergence of human re-infection have raised widespread concerns about a possible short duration of SARS-CoV-2 vaccine protection. Here, we developed a nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD, termed as mRNA-RBD. A single immunization of mRNA-RBD elicited both robust neutralizing antibody and cellular responses, and conferred a near-complete protection against wild SARS-CoV-2 infection in the lungs of hACE2 transgenic mice. Noticeably, the high levels of neutralizing antibodies in BALB/c mice induced by mRNA-RBD vaccination were maintained for at least 6.5 months and conferred a long-term notable protection for hACE2 transgenic mice against SARS-CoV-2 infection in a sera transfer study. These data demonstrated that a single dose of mRNA-RBD provided long-term protection against SARS-CoV-2 challenge. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/33536425/A_single_dose_mRNA_vaccine_provides_a_long_term_protection_for_hACE2_transgenic_mice_from_SARS_CoV_2_ L2 - https://doi.org/10.1038/s41467-021-21037-2 DB - PRIME DP - Unbound Medicine ER -